摘要
目的:研究靶向药物吉非替尼同步个体化放疗治疗晚期非小细胞肺癌的临床疗效。方法:选取100例晚期非小细胞肺癌患者分为放疗组和联合组。放疗组进行单纯个体化放疗治疗;联合组在放疗组基础上采用靶向药物吉非替尼治疗。比较各项指标。结果:(1)联合组对比放疗组的指标均优良,P<0.05。结论:靶向药物吉非替尼同步个体化放疗治疗晚期非小细胞肺癌的临床疗效确切,可有效改善患者预后,延长中位生存期,值得推广。
Objective: To study the targeted drug gefitinib synchronization individualized radiotherapy for advanced non-small cell lung cancer clinical efficacy. Methods: 100 patientswith advanced non-small cell lung cancer patients were divided into radiotherapy group and the combination group. Radiotherapy alone group individualized radiation therapy; combination groupusing targeted drug gefitinib treatment in the radiotherapy group basis. Comparison of the indicators. Results:(1) the combination group index contrast radiotherapy group were excellent, P <0.05. Conclusion: The clinical efficacy of targeted drug gefitinib synchronization individualized radiotherapy for advanced non-small cell lung cancer accurate, may improve prognosis and prolong the mediansurvival period, is worth promoting.
引文
[1]王竞,夏廷毅,王颖杰等.靶向药物同步个体化放疗治疗晚期/转移性非小细胞肺癌的Ⅱ期临床研究[J].癌症进展,2011,09(1):94-101.
[2]蔡勇,白冲.适形放疗联合吉非替尼同步治疗局部晚期老年非小细胞肺癌的疗效[J].中国老年学杂志,2013,33(10):2445-2446.
[3]李金铎,郭志.选择性动脉灌注化疗联合靶向药物治疗非小细胞肺癌多发脑转移[J].中国肺癌杂志,2012,15(5):305-308.
[4]周业琳.非小细胞肺癌脑转移放疗联合靶向治疗的临床分析[D].南昌大学,2012.
[5]王苏.DLL4/Notch信号通路相关蛋白在非小细胞肺癌中的表达及初步结构生物学研究[D].第二军医大学,2011.